A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal...

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Colorectal cancer (CRC) is a major global health concern, with high mortality rates.
• Treatment resistance, particularly in KRAS-mutant CRC, poses a significant challenge due to complex genomic drivers.
• Current targeted therapies are often ineffective against these resistant and complex cancers.

Purpose of the Study:

• To develop a personalized therapeutic strategy for a patient with treatment-resistant, metastatic KRAS-mutant colorectal cancer.
• To identify novel drug combinations by leveraging a patient-specific genomic profile and a high-throughput screening platform.
• To evaluate the efficacy of the identified combination therapy in a clinical setting.

Main Methods:

• Comprehensive genomic analysis of the patient's tumor to identify key driver mutations.
• Development of a transgenic Drosophila hindgut model incorporating orthologs of identified cancer drivers.
• Robotics-based drug screening using the Drosophila model to identify effective drug combinations.
• Clinical administration of the identified combination therapy (trametinib plus zoledronate) to the patient.

Main Results:

• Genomic analysis identified nine key drivers in the patient's tumor.
• The Drosophila model-based screen identified trametinib plus zoledronate as a promising combination.
• The patient exhibited a significant partial response, with stable disease for 11 months.
• Tumor lesions (both target and non-target) showed substantial reduction and stabilization.

Conclusions:

• Personalized therapeutic approaches that address genomic complexity can be effective for treatment-resistant cancers.
• The combination of trametinib and zoledronate shows potential as a novel treatment for KRAS-mutant colorectal cancer.
• This study highlights the utility of advanced genomic analysis and model systems in developing tailored cancer therapies.